Author

C. D. Torrice

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 1

Frequent Co-Authors

C. R. M. Asquith· 2 shared D. J. Crona· 2 shared C. Alamillo-Ferrer· 1 shared C. Grundner· 1 shared C. Joiner· 1 shared D. P. McDonnell· 1 shared G. J. Tizzard· 1 shared J. Byemerwa· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. R. M. Asquith

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A new chemotype of chemically tractable nonsteroidal estrogens based on a thienopyrimidine core.

V. R. Sammeta, J. D. Norris, S. Artham, C. D. Torrice, J. Byemerwa, C. Joiner, S. W. Fanning, D. P. McDonnell, T. M. Willson

The paper identifies a new chemotype of nonsteroidal estrogens based on a thienopyrimidine core through targeted screening and structure-guided optimization.

bioRxiv · Apr 15, 2022Cell Biology

Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines

C. R. M. Asquith, N. Fleck, C. D. Torrice, D. J. Crona, C. Grundner, W. J. Zuercher

The paper identifies novel anti-tubercular compounds from 4-anilinoquinolines and 4-anilinoquinazolines with high potency and low toxicity.

bioRxiv · Jun 18, 2019Pharmacology & Toxicology

Design and evaluation of novel 4-anilinoquinolines and quinazolines as EGFR inhibitors in lung cancer and chordoma

C. R. M. Asquith, K. A. Maffuid, T. Laitinen, C. D. Torrice, G. J. Tizzard, C. Alamillo-Ferrer, K. M. Koshlap, D. J. Crona, W. Zuercher

The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.

bioRxiv · Feb 11, 2019 · PreprintPharmacology & Toxicology